Grufity logoGrufity logo

TherapeuticsMD Inc Stock Research

TXMD

3.45USD-0.20(-5.48%)Market Closed

Market Summary

USD3.45-0.20
Market Closed
-5.48%

TXMD Stock Price

TXMD RSI Chart

TXMD Valuation

Market Cap

32.7M

Price/Earnings (Trailing)

-3.77

Price/Sales (Trailing)

0.37

EV/EBITDA

2.56

Price/Free Cashflow

-0.32

TXMD Price/Sales (Trailing)

TXMD Profitability

EBT Margin

-9.57%

Return on Assets

-6.47%

Free Cashflow Yield

-316.67%

TXMD Fundamentals

TXMD Revenue

Revenue (TTM)

87.5M

Revenue Y/Y

-17.67%

Revenue Q/Q

-26.76%

TXMD Earnings

Earnings (TTM)

-8.7M

Earnings Y/Y

38.92%

Earnings Q/Q

-125.8%

Price Action

52 Week Range

1.9923.00
(Low)(High)

Last 7 days

-21.8%

Last 30 days

-27.1%

Last 90 days

-44.9%

Trailing 12 Months

-77.6%

TXMD Financial Health

Current Ratio

0.5

Debt/Cashflow

-1.1

TXMD Investor Care

Shares Dilution (1Y)

12.12%

Diluted EPS (TTM)

-1.43

Peers (Alternatives to TherapeuticsMD)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
404.8B
94.9B
-5.16% -10.64%
22.56
4.26
1.25% -14.07%
296.8B
28.5B
-5.67% 20.74%
47.53
10.4
0.79% 11.88%
272.8B
59.3B
-1.75% 40.02%
17.88
4.63
21.72% 11.27%
226.4B
100.3B
-8.43% -20.95%
7.22
2.26
23.43% 42.74%
142.7B
46.2B
-7.78% -1.12%
22.55
3.09
-0.49% -9.54%
MID-CAP
4.8B
4.5B
-0.20% -5.41%
-34.17
1.08
7.56% -104.06%
3.3B
2.2M
105.10% 171.03%
-10.52
1.5K
-80.71% -4.88%
SMALL-CAP
1.9B
667.2M
-9.96% 17.66%
31.57
2.87
15.09% 13.64%
1.6B
602.5M
-17.77% -52.80%
-2.74
2.63
18.18% -18.59%
991.7M
478.9M
-11.35% -65.42%
-0.32
2.07
-31.50% -634.70%
792.9M
285.2M
-7.22% -37.95%
3.6
2.78
-27.21% -40.28%
768.8M
114.5M
-15.28% -37.42%
-4.56
6.72
27.90% 57.40%
612.8M
972.1M
-6.94% -26.30%
16.32
0.63
10.54% -19.02%
106.7M
-
2.08% -28.79%
-3.22
2.72
4.98% -2206.89%
32.7M
87.5M
-27.15% -77.57%
-3.77
0.37
-3.70% 94.95%

Financials for TherapeuticsMD

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-4.9%87,489,00091,978,00086,418,00086,951,00090,851,000
Gross Profit-4.1%69,364,00072,359,00067,407,00068,113,00071,169,000
Operating Expenses-11.5%170,573,000192,742,000204,128,000207,883,000210,154,000
  S&GA Expenses-11.5%83,705,00094,581,000103,066,000108,195,000112,189,000
  R&D Expenses-8.2%5,512,0006,005,0006,436,0007,086,0008,060,000
EBITDA82.5%34,325,00018,810,000-142,449,000-135,405,000-
EBITDA Margin91.8%0.390.20-1.65-1.56-
Earnings Before Taxes68.5%-8,375,000-26,570,000-182,053,000-172,415,000-171,542,000
EBT Margin66.9%-0.10-0.29-2.11-1.98-
Interest Expenses-6.5%38,517,00041,202,00037,102,00032,917,00032,953,000
Net Income68.0%-8,665,000-27,120,000-182,053,000-172,415,000-171,542,000
Net Income Margin66.4%-0.10-0.29-2.11-1.98-
Free Cahsflow15.7%-103,429,000-122,661,000-133,852,000-142,727,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-8.4%134146133169210
  Current Assets-11.3%87.0099.0084.00119160
    Cash Equivalents2.1%38.0038.0030.0065.00105
  Inventory9.0%7.006.009.008.007.00
  Net PPE-22.4%1.001.001.001.001.00
Liabilities5.8%182172274263267
  Current Liabilities6.1%17416426525386.00
  Long Term Debt3.1%94.0091.00203188187
    LT Debt, Current3.1%94.0091.0020318815.00
    LT Debt, Non Current-100.0%-172---
  Retained Earnings-2.9%-1,017-988-1,100-1,051-1,008
  Additional Paid-In Capital0.7%969962960958951
Shares Outstanding6.9%9.009.009.009.008.00
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations15.7%-103,408-122,711-133,839-142,693-133,492
  Share Based Compensation-17.7%13,93316,93917,23018,12514,956
Cashflow From Investing0.1%140,802140,651-1,997-2,223-1,203
Cashflow From Financing-13.2%-103,905-91,81128,603129,552159,902

Risks for TXMD

What is the probability of a big loss on TXMD?

100%


Probability that TherapeuticsMD stock will be more than 20% underwater in next one year

97.7%


Probability that TherapeuticsMD stock will be more than 30% underwater in next one year.

86.5%


Probability that TherapeuticsMD stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TXMD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if TherapeuticsMD was unfortunately bought at previous high price.

Drawdowns

Returns for TXMD

Cumulative Returns on TXMD

-27.0%


10-Year Cumulative Returns

-47.0%


7-Year Cumulative Returns

-57.5%


5-Year Cumulative Returns

-63.4%


3-Year Cumulative Returns

What are the long-term rolling returns for TXMD?

FIve years rolling returns for TherapeuticsMD.

Annualized Returns

Which funds bought or sold TXMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
unchanged
-
-212
788
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
unchanged
-
45.00
45.00
-%
2023-02-15
Tejara Capital Ltd
new
-
1,773,780
1,773,780
1.02%
2023-02-15
Steward Partners Investment Advisory, LLC
unchanged
-
73.00
73.00
-%
2023-02-15
Financial Gravity Asset Management, Inc.
new
-
1.00
1.00
-%
2023-02-15
State of Wyoming
sold off
-100
-58,000
-
-%
2023-02-15
HOWE & RUSLING INC
sold off
-100
-
-
-%
2023-02-14
AMERIPRISE FINANCIAL INC
reduced
-0.04
-23,000
126,000
-%
2023-02-14
MONEY CONCEPTS CAPITAL CORP
new
-
39.00
39.00
-%
2023-02-14
STATE STREET CORP
new
-
148,303
148,303
-%

1–10 of 43

Latest Funds Activity

Are funds buying TXMD calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own TXMD
No. of Funds

TherapeuticsMD News

Marketscreener.com

North American Morning Briefing : Some Calm -2-.

Marketscreener.com,
3 days ago

The Pharma Letter

Kalkine Media

Schedule 13G FIlings of TherapeuticsMD

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Aug 30, 2022
rubric capital management lp
18.27%
1,721,953
SC 13D/A
Jul 08, 2022
blackrock inc.
1.4%
122,138
SC 13G/A
Jun 03, 2022
beryl capital management llc
1.5%
126,229
SC 13G
Mar 23, 2022
smith robert j
5.38%
23,103,292
SC 13D/A
Feb 14, 2022
price t rowe associates inc /md/
0.1%
649,807
SC 13G/A
Feb 01, 2022
blackrock inc.
5.9%
24,894,812
SC 13G/A
Jul 07, 2021
flynn james e
4.90%
20,662,810
SC 13G
Feb 16, 2021
price t rowe associates inc /md/
6.2%
18,869,212
SC 13G/A
Feb 10, 2021
vanguard group inc
4.39%
13,165,644
SC 13G/A
Feb 08, 2021
fmr llc
-
0
SC 13G/A

TXMD Fair Value

TherapeuticsMD fair value in different scenarios

The table shows the Fair Value estimates for TherapeuticsMD for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

1.02

-70.43%

7.32

112.17%

17.18

397.97%
Current Inflation

-

-

-

-

0.38

-88.99%

5.84

69.28%

14.34

315.65%
Very High Inflation

-

-

-

-

-

-

4.09

18.55%

11.00

218.84%

Historical TherapeuticsMD Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of TherapeuticsMD

View All Filings
Date Filed Form Type Document
Feb 27, 2023
8-K
Current Report
Feb 23, 2023
4
Insider Trading
Feb 23, 2023
4
Insider Trading
Feb 22, 2023
4/A
Insider Trading
Feb 13, 2023
5
Insider Trading
Jan 30, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 18, 2023
8-K
Current Report
Jan 12, 2023
8-K
Current Report
Jan 06, 2023
8-K/A
Current Report

Latest Insider Trading transactions for TXMD

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-27
Donegan Michael C
sold
-249
5.09
-49.00
prin. fin. and acctg. officer
2023-01-26
Donegan Michael C
acquired
-
-
5,940
prin. fin. and acctg. officer
2023-01-26
Donegan Michael C
sold
-8,371
5.0796
-1,648
prin. fin. and acctg. officer
2023-01-24
Donegan Michael C
sold
-37.1707
5.3101
-7.00
prin. fin. and acctg. officer
2023-01-23
Donegan Michael C
sold
-6,950
5.3383
-1,302
prin. fin. and acctg. officer
2023-01-23
Donegan Michael C
acquired
-
-
4,365
prin. fin. and acctg. officer
2022-12-30
Rubric Capital Management LP
sold
-38,657,000
1,333
-29,000
-
2022-12-30
Rubric Capital Management LP
back to issuer
-38,657,000
1,333
-29,000
-
2022-12-09
Rubric Capital Management LP
bought
90,284
6.09
14,825
-
2022-12-09
Bernick Brian
sold
-2,019
6.3121
-320
co-chief executive officer

1–10 of 50

Hugh O'Dowd
420
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TXMD Income Statement

2022-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Total revenue, net$ 20,917,000$ 25,406,000$ 68,811,000$ 68,273,000
Cost of goods sold3,788,0005,282,00013,388,00014,101,000
Total gross profit17,129,00020,124,00055,423,00054,172,000
Operating expenses:    
Selling and marketing19,129,00030,005,00061,703,00086,193,000
General and administrative17,635,00028,435,00055,445,00066,691,000
Research and development1,112,0001,605,0004,092,0005,666,000
Total operating expenses37,876,00060,045,000121,240,000158,550,000
Loss from operations(20,747,000)(39,921,000)(65,817,000)(104,378,000)
Other (expense) income:    
Gain on sale of business  143,384,000 
Expense for accretion of Mandatory Redeemable Preferred Stock(3,457,000) (3,457,000) 
Fair value loss on Lender Warrants derivative liability(76,000) (76,000) 
Loss on extinguishment of debt  (8,380,000) 
Interest expense and other financing costs(4,833,000)(7,518,000)(30,941,000)(25,341,000)
Other (expense) income, net(112,000)19,000(128,000)264,000
Total other (expense) income, net(8,478,000)(7,499,000)100,402,000(25,077,000)
(Loss) income before income taxes(29,225,000)(47,420,000)34,585,000(129,455,000)
(Benefit) provision for income taxes(260,000)0290,0000
Net (loss) income$ (28,965,000)$ (47,420,000)$ 34,295,000$ (129,455,000)
(Loss) earnings per common share, basic$ (3.13)$ (5.62)$ 3.86$ (16.68)
Weighted average common shares, basic9,2618,4448,8777,762
(Loss) earnings per common share, diluted$ (3.13)$ (5.62)$ 3.73$ (16.68)
Weighted average common shares, diluted9,2618,4449,2057,762
Comprehensive (loss) income:    
Net (loss) income$ (28,965,000)$ (47,420,000)$ 34,295,000$ (129,455,000)
Comprehensive (loss) income(28,965,000)(47,420,000)34,295,000(129,455,000)
Product [Member]    
Total revenue, net$ 20,917,00024,456,00068,327,00067,039,000
License and Service [Member]    
Total revenue, net $ 950,000$ 484,000$ 1,234,000

TXMD Balance Sheet

2022-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash$ 27,080$ 65,122
Restricted cash11,250 
Accounts receivable, net of allowance for credit losses of $1,621 and $1,334 as of September 30, 2022 and December 31, 2021, respectively32,15736,176
Inventory6,7017,622
Prepaid and other current assets10,29010,548
Total current assets87,478119,468
Fixed assets, net5511,199
License rights and other intangible assets, net37,87640,318
Right of use assets7,7498,234
Other non-current assets253253
Total assets133,907169,472
Current liabilities:  
Debt, net93,602188,269
Lender Warrants derivative liability2,058 
Make-whole payment derivative liability1,751 
Mandatory Redeemable Preferred Stock19,709 
Accounts payable13,38320,318
Accrued expenses and other current liabilities43,56844,304
Total current liabilities174,071252,891
Operating lease liabilities7,5538,063
Other non-current liabilities5542,139
Total liabilities182,178263,093
Commitments and contingencies (Note 9)
Stockholders' deficit:  
Preferred stock, par value $0.001; 10,000 shares authorized, 22 issued and included in liabilities due to their redemption provisions
Common stock, par value $0.001; 12,000 shares authorized, 9,467 and 8,598 (adjusted for the 50-for-1 reverse stock split) shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively99
Additional paid-in capital968,785957,730
Accumulated deficit(1,017,065)(1,051,360)
Total stockholders' deficit(48,271)(93,621)
Total liabilities and stockholders' deficit$ 133,907$ 169,472